Recent Updates
Recently added Catalysts
CV Positive Sentiment Score: 70/100

CapsoVision to Release Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 26, 2026

Key Takeaway: CapsoVision, Inc. will announce its fourth quarter and full year 2025 financial results on March 26, 2026. A conference call will follow the release to discuss the results and provide updates. The company focuses on advanced imaging and AI-enabled solutions for gastrointestinal diseases, with products like CapsoCam Plus® and the upcoming CapsoCam Colon™.

Market Sentiment Analysis

POSITIVE FACTORS

  • CapsoVision is set to release its financial results, indicating ongoing operations.
  • The company is developing innovative AI-enabled capsule endoscopy solutions.
  • CapsoVision's products aim to enhance gastrointestinal disease detection.

Full Press Release Details

Conference Call Scheduled for Thursday, March 26, 2026, at 4:30 pm ET
SARATOGA, Calif., March 12, 2026(GLOBE NEWSWIRE)-- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that the company will release fourth quarter and full year 2025 financial results on Thursday, March 26, 2026, after the close of market. CapsoVision will host a corresponding conference call and a live webcast at 1:30 pm PT / 4:30 pm ET on the same day to discuss the results and provide a corporate update.
Individuals interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and referencing conference ID 2525025, or from the webcast link on theEventspage in the investor relations section of the company’s website.To access the replay, please register via the webcast link on theEventspage. The webcast will be available for one year following the completion of the call.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visitwww.capsovision.com.

Investor Relations ContactLeigh SalvoNew Street Investor RelationsInvestors@CapsoVision.com

Media ContactLeslie Strickler and Paul SpicerÊtre Communicationsleslies@etrecommunications.com| (804) 240-0807pauls@etrecommunications.com| (804) 503-9231

Frequently Asked Questions

When will CapsoVision release its financial results?

CapsoVision will release its financial results on March 26, 2026.

What products does CapsoVision develop?

CapsoVision develops advanced imaging and AI-enabled capsule endoscopy solutions.

How can I listen to the conference call?

Listeners can dial (800) 715-9871 for domestic calls or (646) 307-1963 for international calls.

What is CapsoCam Plus®?

CapsoCam Plus® is a wire-free capsule endoscope for high-resolution visualization of the small bowel.

What is the upcoming product from CapsoVision?

The next product is CapsoCam Colon™, designed for non-invasive colon imaging and polyp detection.

Last updated: Mar 13, 2026